期刊文献+

新型铂类化合物LLC-0601与舒铂对SD大鼠的肝毒性 被引量:2

Hepatotoxicity of heptaplatin and a new platinum complex LLC-0601 in SD rats
下载PDF
导出
摘要 目的观察新型铂类化合物LLC-0601与舒铂对SD大鼠的肝毒性,探讨其可能的毒性作用机制。方法 雄性SD大鼠尾静脉iv给予顺铂2mg.kg-1(阳性对照)、舒铂40mg.kg-1、LLC-060140和70mg.kg-1,连续2d,间隔5d,共6次,末次给药后恢复期28d,观察动物一般状况,并于给药末期和恢复28d后检测血清谷丙转氨酶(GPT),谷草转氨酶(GOT),碱性磷酸酶(ALP),总蛋白(TP),白蛋白(ALB)和总胆红素(T-Bil),肝质量与系数,组织匀浆谷胱甘肽过氧化物酶(GSH-Px),超氧化物歧化酶(T-SOD),微量丙二醛(MDA)及光学显微镜进行病理组织学检查。结果与正常对照组相比,LLC-060140mg.kg-1组各项检测指标未见明显异常,其余给药组动物均出现精神差、少食、少动、竖毛、毛发无光泽以及体质量下降;给药末期血清生化检测舒铂组GPT升高,TP和ALB降低(P<0.05);与正常对照组相比,顺铂、舒铂和LLC-060170mg.kg-1组肝质量明显降低(P<0.05),顺铂和舒铂组肝系数明显降低(P<0.05);顺铂、舒铂和LLC-060170mg.kg-1组肝组织匀浆中GSH-Px和T-SOD降低,各给药组MDA均升高(P<0.05);顺铂、舒铂和LLC-060170mg.kg-1组肝病理组织学均出现不同程度肝细胞点灶状坏死,肝窦内淋巴细胞浸润,以舒铂组病变程度最重。恢复期顺铂组病理组织学病变较给药末期重,出现延迟性毒性反应,其余各给药组各项检测指标均基本恢复。结论顺铂、舒铂和LLC-0601均可引起大鼠肝损伤,其机制与药物引起的组织过氧化损伤有关。 OBJECTIVE To investigate the hepatotoxicity of heptaplatin and LLC-0601 in SD rats,and to explore the toxic mechanisms.METHODS Rats were respectively injected with cisplatin 2 mg·kg-1(positive control),heptaplatin 40 mg·kg-1 and LLC-0601 40 and 70 mg·kg-1,once a day,for 2 d,and then an inteval for 5 d,all 3 courses for 6 injections,and then rats restored for 28 d.After the last 24 h after administration and after restoration 28 d,the rats were inspected for their general condition.Serum biochemistry indices glutamic pyruvic transaminase(GPT),glutamic oxaloacetic transaminase(GOT),alkaline phosphatase(ALP),total protein(TP),albumin(ALB) and total bilirubin(T-Bil) were detected.Liver mass and coefficients were detected.The activity of glutathione peroxidase(GSH-Px),total superoxide dismutase(T-SOD) and malondialdehyde(MDA) was examined and liver histopathology was observed.RESULTS Compared with normal control group,rats in treated groups except LLC-0601 70 mg·kg-1 appeared to be dispirited,and mat,food intake decreased,significant vertical hair phenomena,with a reduction of activity.GPT was higher,but TP and ALB were lower in heptaplatin group(P0.05).Compared with normal control group,liver mass and organ coefficients,GSH-Px and T-SOD were lower in the drug-treated groups(P0.05).While MDA was significantly higher(P0.05).Liver tissue in cisplatin,heptapletin and LLC-0601 70 mg·kg-1 groups showed focal necrosis and sinusoidal lymphocytic infiltration of liver cells.After 28 d restoration all indices returned to normal except cisplatin group.CONCLUSION Heptaplatin and LLC-0601 can induce liver damage and the mechanism may be related to their oxidative damage.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2011年第4期369-374,共6页 Chinese Journal of Pharmacology and Toxicology
基金 云南省教育厅科学研究基金项目资助(09J0055)~~
关键词 LLC-0601 铂化合物 毒性作用 LLC-0601 platinum compounds liver toxic actions
  • 相关文献

参考文献14

  • 1Wheate N J, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials[J]. Dalton Trans, 2010, 39(35) :8113-8127.
  • 2Wong E, Giandomenico CM. Current status of platinum- based antitumor drugs [ J ]. Chem Rev, 1999, 99 (9) : 2451-2466.
  • 3Hong WS, Kim HT, Kim KH, Kim DK. In vitro antitu- mor activity of a new platinum complex, cis-malonato [ (4 R, 5 R ) -4,5-bis ( aminomethyl ) -2 -isopropyl-1,3-di- oxolane] platinum( II ) (SKI 2053R) , against human lung and stomach cancer cell lines [ J ]. Anticancer Res, 1995, 15(1) :51-54.
  • 4Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, et al. Antitumor activity of cis-malonato[ (4R,SR)-4,5-bis ( aminomethyl ) -2-isopropyl-1,3-clioxolane ] platinum ( II ), a new platinum analogue, as an anticancer agent[ J]. Cancer Chemother Pharmacol, 1995, 35( 5 ) :441-445.
  • 5Zang DY, Lee KH, Lee JS, Lee JH, Kim WK, Kim SH, et al. Phase H trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer[J]. Am J Clin Oncol , 1999, 22(5) :495-498.
  • 6Kim NK, Kim TY, Shin SG, Park YI, Lee JA, Cho YB, et al. A Phase I study of cis-malonato[ (4R,5R) - 4,5-bis(aminomethyl) -1,3-dioxolane ] platinum( II ) in patients with advanced malignancies [ J ]. Cancer, 2001,91(8) :1549-1556.
  • 7谢恩C.加德,著.范玉明,李毅民,张舒,译.国外药学专著译丛-药物安全性评价[M].北京:化学工业出版社,2006:202-208.
  • 8Tsang RY, A1-Fayea T, Au HJ. Cisplatin overdose: toxicities and management [ J ]. Drug Saf, 2009, 32 (12) :1109-1122.
  • 9Kim NK, Im SA, Kim DW, Lee MH, Jung CW, Cho EK, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma[ J]. Cancer, 1999, (7) :1109-1115.
  • 10Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, et al. Randomized, multicenter, phase In trial of heptaplatin 1-hour infusion and 5 - fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with ad- vanced gastric cancer[J]. Cancer Res Treat, 2009, 41 (1) :12-18.

同被引文献22

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部